28.02.2024 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate .
Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 2,200,000 shares, a decline of 24.9% from the October 15th total of 2,930,000 shares. Based on an average daily volume of 486,200 […]
13.11.2023 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2023 and .
Kezar Life Sciences (NASDAQ:KZR – Get Rating) had its price target lowered by Wells Fargo & Company from $14.00 to $13.00 in a research report report published on Friday, The Fly reports. Several other brokerages have also recently weighed in on KZR. HC Wainwright reduced their price objective on Kezar Life Sciences from $21.00 to […]
09.11.2022 - Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two .